The Venture Codex

Participated · Series B · Aug 2026

Vaderis is developing engasertib (VAD044), an investigational once-daily oral selective allosteric AKT1/2 inhibitor intended to treat hereditary hemorrhagic telangiectasia (HHT). The company has advanced engasertib into pivotal development following positive proof-of-concept and long-term extension data published in The New England Journal of Medicine. Vaderis has initiated HEROIC, a global Phase 3 randomized, double-blind, placebo-controlled study enrolling patients across North America, South America and Europe. The company intends to use proceeds from its $152 million Series B to support operations through regulatory submissions and potential U.S. approval. Vaderis is headquartered in Basel, Switzerland, with a U.S. subsidiary in Lincolnshire, Illinois. The company positions engasertib as a potential first approved therapy specifically developed for people living with HHT.

Participated · Equity · Jul 2026

Xeltis develops implantable vascular and cardiovascular devices based on its Restorex® platform, which uses an advanced polymer implant that transforms into the patient’s own tissue and is gradually absorbed. Its lead product, aXess™, is an implantable blood vessel for hemodialysis vascular access that has received CE Mark approval and is being commercially deployed in Europe. The company is enrolling a US pivotal trial of aXess™ (now >50% enrolled) and is preparing for FDA submission and a US market launch. Xeltis plans to use recent funding to support European commercial rollout, upscale manufacturing and advance its XABG and XPAD clinical programs. Financially, the company raised €50m in 2025 from the European Investment Bank and existing shareholders and added €20.5m in 2026 from new and existing investors to fund its next phase of clinical, regulatory and commercial execution.

Participated · Series A · Jun 2026

Founded in 2021, RQ Bio is developing long-acting monoclonal antibody therapeutics aimed at providing immediate and durable protection against seasonal influenza. Its lead programme, RQB01, is in IND-enabling studies and is designed to deliver broad strain coverage and extended duration of action via a differentiated dual mechanism targeting conserved epitopes. The company aims to provide season-long protection with a single administration, particularly for immunocompromised and high-risk patients. RQ Bio has an experienced team with prior success in developing long-acting antiviral antibodies and is backed by a syndicate of life sciences investors. The recent $115 million Series A will fund clinical development of RQB01 and further advance the company's antibody discovery platform. Leadership was strengthened with the appointment of Christian S. Schade as Executive Chairman.

Led · Equity · Apr 2026

Onward commercializes ARC Therapy, a suite of neurostimulation technologies founded on research from CHUV and UNIL by Grégoire Courtine, Jocelyne Bloch, and Vincent Delattre. Its ARC-EX® system is already cleared for use in the United States and Europe, positioning the company as a commercial-stage player. The implantable ARC-IM® platform is in clinical evaluation, including studies targeting blood pressure instability in spinal cord injury patients. Onward recently raised more than €40 million, including €25 million from EQT Life Sciences, which extends its financial runway into early 2028. The company plans to use the new capital to accelerate product development, expand commercial activities in key markets, and support further clinical validation and regulatory work.

Participated · Series C · Feb 2026

Neurent Medical is a med-tech company focused on transforming care for chronic inflammatory sinonasal diseases, beginning with chronic rhinitis. Its flagship NEUROMARK System employs proprietary Impedance Controlled Radiofrequency technology to gently disrupt hyperactive posterior nasal nerves, providing durable symptom relief with minimal downtime. The company positions the platform as a differentiated, clinician-friendly alternative that tackles the root cause of rhinitis rather than merely managing symptoms. Headquartered in Galway, Ireland, with U.S. operations in Braintree, Massachusetts, Neurent Medical is expanding commercial availability and building further clinical evidence to support adoption. The newly secured capital will accelerate market penetration, support additional clinical studies across broader populations, and fund development of future indication and product pipeline extensions. The firm has attracted prominent medtech investors and added new board members to guide this next growth phase. No revenue or user metrics were disclosed in the article, but leadership emphasizes scaling sales and broadening evidence as immediate priorities.